News & Analysis as of

Equity Financing Life Sciences Private Equity

Cooley LLP

Deal Count Increases and Invested Capital Down for Late-Stage Rounds; Valuations Rise and Pay-to-Play Reaches 10.1%

Cooley LLP on

Cooley handled 238 reported venture capital financings in Q2 2025, representing $6.5 billion of invested capital. Deal count increased by more than 20% across all stages of financing compared to the previous quarter, with...more

McDermott Will & Schulte

Key Takeaways | Alternative Capital-Raising Strategies in Challenging Times

During this session, the panelists shared alternative capital-raising financing strategies, including venture capital (VC), accelerators, spin-outs, bridge financing, licensing, and government agency support. They also...more

Hogan Lovells

Strategic financial options for clinical stage life sciences companies in a troubled equity market

Hogan Lovells on

Early 2023 has seen new and unprecedented financial challenges for clinical stage life sciences companies. The financing rounds of 2021 and 2022 are starting to run off, while at the same time the equity markets are either...more

McGuireWoods LLP

Healthcare & Life Sciences Private Equity Deal Tracker: Warburg Pincus to Acquire Stake in Hygenia

McGuireWoods LLP on

Warburg Pincus has announced it will invest in Hygenia. Warburg Pincus, headquartered in New York, is a PE firm that takes a long-term perspective and invest in businesses at all stages of development. It invests...more

McGuireWoods LLP

Healthcare & Life Sciences Private Equity Deal Tracker: Scholar Rock Secures $36 Million in Funding

McGuireWoods LLP on

Scholar Rock, based in Cambridge, Mass., is a biotechnology company focused on developing drugs that selectively target supracellular activation of growth factors in the disease microenvironment. The company’s initial drug...more

McGuireWoods LLP

Healthcare & Life Sciences Private Equity Deal Tracker: Metacrine Secures $36 Million in Financing

McGuireWoods LLP on

Metacrine, based in San Diego, Calif., is a biotechnology company focused on advancing research in nuclear hormone receptors for treatment of metabolic diseases originated at the Salk Institute for Biological Studies....more

6 Results
 / 
View per page
Page: of 1

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
- hide
- hide